Roivant Sciences Ltd.
General ticker "ROIV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.5B (TTM average)
Roivant Sciences Ltd. follows the US Stock Market performance with the rate: 59.7%.
Estimated limits based on current volatility of 1.7%: low 20.34$, high 21.06$
Factors to consider:
- Total employees count: 908 (+0.4%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Senior management dependency, Transition risks, Labor/talent shortage/retention, Strategic risks and growth management, Geopolitical risks
- Current price 50.2% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [7.52$, 14.10$]
- 2026-03-31 to 2027-03-31 estimated range: [7.43$, 13.94$]
Financial Metrics affecting the ROIV estimates:
- Negative: with PPE of -13.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.89 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 86.22 > 63.39
- Positive: Inventory ratio change, % of -52.59 <= -0.75
Short-term ROIV quotes
Long-term ROIV plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | $61.28MM | $32.71MM | $29.05MM |
| Operating Expenses | $1,236.60MM | $-4,464.32MM | $1,032.35MM |
| Operating Income | $-1,175.32MM | $4,497.03MM | $-1,003.29MM |
| Non-Operating Income | $-49.52MM | $70.82MM | $321.70MM |
| Interest Expense | $27.97MM | $34.78MM | $0.00MM |
| R&D Expense | $622.96MM | $439.91MM | $550.41MM |
| Income(Loss) | $-1,224.83MM | $4,567.86MM | $-681.59MM |
| Taxes | $5.19MM | $21.50MM | $48.17MM |
| Other Income(Loss) | $114.56MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-1,009.03MM | $4,466.65MM | $-171.98MM |
| Stockholders Equity | $1,157.77MM | $5,968.58MM | $4,687.60MM |
| Inventory | $2.76MM | $35.25MM | $0.00MM |
| Assets | $2,389.60MM | $7,222.48MM | $5,436.94MM |
| Operating Cash Flow | $-843.39MM | $-765.27MM | $-839.45MM |
| Capital expenditure | $12.69MM | $1.38MM | $4.60MM |
| Investing Cash Flow | $-44.27MM | $5,203.62MM | $-1,766.29MM |
| Financing Cash Flow | $499.46MM | $419.36MM | $-1,219.79MM |
| Earnings Per Share** | $-1.42 | $5.70 | $-0.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.